Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in COVID-19
NCT04371640Phase 1Withdrawn
- Start
- Jul 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Sirolimus with Placebo (2 arms). Primary endpoint: Change in SARS-CoV-2 viral burden at Day 7. Planned start Jul 2020; status: withdrawn.
02
Drugs
sirolimus
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04371640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04371640.